Magnolol, three derivatives of magnolol and honokiol were initially tested on NRAS‐ and BRAF‐mutant melanoma cells with the aim to identify whether any of the derivatives showed an improved efficacy over the original compound. The gene discussed is BRAF; the disease is melanoma.